SecurityBSFT / BroadSoft, Inc. (11133B409)
IndustryPrepackaged Software
Common Shares Outstanding31,649,386 shares (as of 2017-09-30)
Total Insiders14
Total Directors9
Total Officers6

Stock Insider Trading (from SEC Form 4)

BroadSoft, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

BSFT / BroadSoft, Inc. insiders include DIPALMA DINO Magelli Paul, Maine Douglas L, Tholen James Albert, Tessler Michael, Geisse Andrew M, SAGE GAVIN EVA, GAVIN JOHN J JR, Dourgarian Dennis, and Dietze Jane A, Markley John D. Jr., Hoffpauir Scott D., Bernardi David, BEHBEHANI TAHER G., .

Insider Roster

Insider Dir Off 10% Shares Owned
GAVIN JOHN J JR Director
X 0
Dietze Jane A Director
X 0
Bernardi David Director
X 0
SAGE GAVIN EVA Director
X 0
Maine Douglas L Director
X 0
Magelli Paul Director
X 0
Geisse Andrew M Director
X 0
Markley John D. Jr. Director
X 0
DIPALMA DINO Chief Revenue Officer
X 0
BEHBEHANI TAHER G. Chief Marketing Officer
X 0
Hoffpauir Scott D. Chief Technology Officer
X 0
Tholen James Albert Chief Financial Officer
X 0
Tessler Michael President & CEO, Director
X X 0
Dourgarian Dennis Chief Accounting Officer
X 0

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-02-01 4 Dourgarian Dennis D D 55.00 -32,420 0
2018-02-01 4 Tessler Michael D D 55.00 -288,134 0
2018-02-01 4 Tessler Michael A D 67,205 288,134
2018-02-01 4 Tholen James Albert D D 55.00 -109,440 0
2018-02-01 4 Tholen James Albert A D 34,983 109,440
2018-02-01 4 Hoffpauir Scott D. By The Scott D. Hoffpauir 2000 Family Irrevocable Trust D I 55.00 -16,666 0
2018-02-01 4 Hoffpauir Scott D. D D 55.00 -112,974 0
2018-02-01 4 Hoffpauir Scott D. A D 34,983 112,974
2018-02-01 4 BEHBEHANI TAHER G. D D 55.00 -68,573 0
2018-02-01 4 BEHBEHANI TAHER G. A D 7,301 68,573
2018-02-01 4 DIPALMA DINO D D 55.00 -26,500 0
2018-02-01 4 DIPALMA DINO A D 6,500 26,500
2018-02-01 4 Markley John D. Jr. D D 55.00 -22,089 0
2018-01-19 4 Markley John D. Jr. G D -750 22,089
2018-02-01 4 Geisse Andrew M D D 55.00 -11,689 0
2018-02-01 4 Magelli Paul D D 55.00 -7,517 0
2018-02-01 4 Maine Douglas L D D 55.00 -52,798 0
2018-02-01 4 SAGE GAVIN EVA D D 55.00 -5,022 0
2018-02-01 4 Bernardi David D D 55.00 -9,038 0
2018-02-01 4 Dietze Jane A D D 55.00 -5,640 0
2018-02-01 4 GAVIN JOHN J JR D D 55.00 -17,321 0
2018-01-27 4 Dourgarian Dennis F D 54.95 -26 32,420
2018-01-20 4 BEHBEHANI TAHER G. F D 55.00 -1,120 61,272
2018-01-17 4 Hoffpauir Scott D. S X D 54.96 -4,448 94,657 5,202,349
2018-01-14 4 Tessler Michael F D 54.85 -3,211 220,929
2018-01-14 4 Hoffpauir Scott D. F D 54.85 -1,506 99,105
2018-01-14 4 Tholen James Albert F D 54.85 -1,414 74,457
2018-01-14 4 BEHBEHANI TAHER G. F D 54.85 -983 62,392
2018-01-01 4 Dourgarian Dennis F D 54.90 -287 32,446
2017-12-31 4 Dourgarian Dennis F D 54.90 -380 32,733
2017-12-18 4 Hoffpauir Scott D. S X D 54.66 -4,448 100,611 5,499,397
2017-11-27 4 Tessler Michael F D 54.80 -3,329 224,140
2017-11-27 4 Hoffpauir Scott D. F D 54.80 -1,815 105,059
2017-11-27 4 Dourgarian Dennis F D 54.80 -187 33,113
2017-11-27 4 Tholen James Albert F D 54.80 -1,700 75,871
2017-11-27 4 BEHBEHANI TAHER G. F D 54.80 -1,119 63,375
2017-11-17 4 Hoffpauir Scott D. S X D 54.57 -4,448 106,874 5,832,114
2017-11-05 4 Dourgarian Dennis F D 54.95 -529 33,300
2017-10-27 4 Dourgarian Dennis F D 54.90 -23 33,829
2017-10-20 4 BEHBEHANI TAHER G. F D 53.90 -1,560 64,494
2017-10-17 4 Hoffpauir Scott D. S X D 52.89 -4,448 111,322 5,887,821
2017-10-14 4 Tessler Michael F D 53.15 -4,431 227,469
2017-10-14 4 Hoffpauir Scott D. F D 53.15 -1,950 115,770
2017-10-14 4 Tholen James Albert F D 53.15 -1,822 77,571
2017-10-14 4 BEHBEHANI TAHER G. F D 53.15 -1,107 66,054
2017-10-01 4 Dourgarian Dennis F D 50.30 -257 33,852
2017-09-30 4 Dourgarian Dennis F D 50.30 -377 34,109
2017-09-18 4 Hoffpauir Scott D. S X D 51.50 -4,448 117,720 6,062,580
2017-09-01 4 Hoffpauir Scott D. S X D 50.00 -8,896 122,168 6,108,400
2017-08-30 4 Hoffpauir Scott D. S X D 48.00 -13,344 131,064 6,291,072
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...